Neurostimulation startup Neuros Medical, which is developing a device to block the chronic pain of amputees, has secured a new investor in RiverVest Venture Partners.
RiverVest will participate in Neuros’ next funding round, which is expected to close in a few months and is being led by existing investor Glengary. Neuros CEO Jon Snyder has said the Cleveland-area company is targeting $3.5 million for the round, which the company is labeling a series A1.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Neuros is developing a device that uses a pacemaker-sized generator and an electrode to stimulate nerves to block pain from amputations — sometimes called stump pain — without the use of drugs. In November, Neuros received regulatory approval to begin a pilot clinical trial of the device.
Snyder has said he anticipates market launch of the device sometime in 2014.
Neuros raised $1.8 million in 2009. A year later, the company received a $1.5 million grant from the U.S. Department of Defense, as the device holds promise in helping relieve pain for soldiers who have lost limbs.
St. Louis-based RiverVest has enjoyed a strong run recently with its healthcare investments. The venture firm said it exited four healthcare portfolio companies last year, with sales to the likes of industry giants Medtronic and Pfizer.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
[Photo from flickr user 1-25_sbct]